An interventional study of Nicotine Patch in Smoking Cessation, sponsored by University of Colorado, Denver. Completed. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-02-11.
Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Health services research
The study is to understand whether distribution of two different supplies of nicotine patches through a telephone quitline has an effect on quit rates. The two different supplies are four vs. eight (in two separate four-week mailings) weeks of nicotine patches. The hypothesis is that eight weeks will be slightly more efficacious but four weeks will be more cost-effective.
University of Colorado, Denver is the lead sponsor of 1,499 studies on the registry; 315 are open to participants now.
Of its 139 completed or terminated interventional studies of FDA-regulated products, 89 (64%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
participants receive one 4-weeks supply of nicotine patches
Drug: Nicotine Patch
participants receive up to 8 weeks of nicotine patches in up to two 4-week supplies
Drug: Nicotine Patch
nicoderm patches are distributed in two different supplies through a telephone quitline
Also known as: Nicoderm Committed Quit patches
7-day smoking abstinence
Time frame: 7 days
6-month smoking abstinence
Time frame: 6 months
cost-effectiveness
cost per quit of each study arm will be calculated based on the total costs of the intervention from actual utilization data (nicotine patch costs + counseling call costs) and quit rates
Time frame: 6 months
No study locations are listed for this record.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Colorado, Denver